Osmotica Pharmaceuticals (NASDAQ:OSMT) and ANCHIANO THERAP/S (NASDAQ:ANCN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.
This is a breakdown of current ratings and target prices for Osmotica Pharmaceuticals and ANCHIANO THERAP/S, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional & Insider Ownership
11.7% of Osmotica Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.2% of ANCHIANO THERAP/S shares are owned by institutional investors. 4.7% of Osmotica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Osmotica Pharmaceuticals and ANCHIANO THERAP/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Osmotica Pharmaceuticals and ANCHIANO THERAP/S’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Osmotica Pharmaceuticals||$263.70 million||0.62||-$109.40 million||($0.51)||-6.24|
|ANCHIANO THERAP/S||N/A||N/A||-$13.28 million||($5.25)||-0.59|
ANCHIANO THERAP/S has lower revenue, but higher earnings than Osmotica Pharmaceuticals. Osmotica Pharmaceuticals is trading at a lower price-to-earnings ratio than ANCHIANO THERAP/S, indicating that it is currently the more affordable of the two stocks.
Osmotica Pharmaceuticals beats ANCHIANO THERAP/S on 5 of the 8 factors compared between the two stocks.
About Osmotica Pharmaceuticals
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201 for treating Blepharoptos. In addition, the company's non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; Hydromorphone ER for treating; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate to treat hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex ANDAs and other ANDAs for various treatments. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
About ANCHIANO THERAP/S
Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.